Anna Turetsky

Dr. Anna Turetsky has served as a board member of Verseau since March 2021 and was previously a board observer.

Anna Turetsky joined The Mark Foundation for Cancer Research (MFCR) as Principal, Venture Investments in November 2019 to launch and lead the foundation’s venture arm. She currently represents MFCR on the boards of Verseau, Accent Therapeutics, C2i Genomics, and Interius BioTherapeutics.

Prior to this, Anna was a Vice President at Lightstone Ventures, a global, early-stage venture fund investing in the biopharmaceutical and medical device sectors. She played a major role in the firm’s investments in Tizona Therapeutics, Gemini Therapeutics (NASDAQ: GMTX), Disarm Therapeutics (acquired by Eli Lilly), Locanabio, and Cyteir Therapeutics, and served as a board observer for these companies. Anna’s additional work experience includes internships and strategic consulting for corporate venture funds and biotech companies.

Anna holds a Ph.D. in biophysics from Harvard University, where she was an NSF Graduate Research Fellow, and a B.A. in biochemistry from the University of Pennsylvania, where she was a Vagelos Science Scholar.